January 28, 2022
One down one to go
Finally, at long last the FDA has officially approved the Omnipod 5, which puts Dexcom in the on-deck circle as we suspect the G7 will be approved soon. While this news was anticipated it couldn’t come at a better time for Insulet stakeholders who like everyone else in MedTech has been beaten like a rug. It also sets the scenario we described in a previous post – let’s review – it will take Insulet a few quarters to get things moving with the 5 – the fourth quarter is traditionally the strongest quarter for insulin pump sales – Covid seems to . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.
